Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016053 (fibromyalgia)
 4,687 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The fibromyalgia syndrome (FS) is a chronic pain disorder frequently affecting women of fertile age. However, the relationship of FS and pregnancy has been given little attention. In the present retrospective analysis, based on personal interviews, the influence on FS symptomatology by pregnancy, abortion, menstruation, use of oral contraceptives, and breast feeding was investigated. Twenty-six women with an established diagnosis of FS and a total of 40 pregnancies during disease were included in the study. With the exception of one patient, all women described worsening fibromyalgia symptoms during pregnancy with the last trimester experienced as the worst period. A new change of fibromyalgia symptoms within 6 months after delivery was reported for 37 of the 40 pregnancies, to the better in four and to the worse in 33 cases, resulting in a prolonged sick leave for 14 patients. An increase in depression and anxiety was a prominent problem in the post partum period. FS had no adverse effect on the outcome of pregnancy or the health of the neonate. In the majority of patients with FS, hormonal changes connected with abortion, use of hormonal contraceptives, and breast feeding did not modulate symptom severity. A pre-menstrual worsening of symptoms was recorded by 72% of the patients. Comparing the 26 patients who had borne children during disease with 18 patients who had all their children before the onset of FS revealed a negative effect of pregnancy and the post partum period of FS and increased functional impairment and disability in the 26 patients.
 ...
PMID:The effect of reproductive events and alterations of sex hormone levels on the symptoms of fibromyalgia. 938 46

The plants of genus Dipsacus, with a wide distribution in Europe, Asia, and Africa, have been used as medicinal agents to treat several diseases, including lime disease, fibromyalgia, bone fracture, and abortion, and especially the Alzheimer's disease and cancer. A large number of studies on plants of genus Dipsacus has revealed cytoprotective properties, inhibition of HIV-1 reverse transcriptase, antinociceptive, and antimicrobial effects, etc. This review compiles all chemical constituents isolated, mainly triterpenoids, iridoids, phenolics, and alkaloids, from the genus Dipsacus over the past few decades together with their structural features, biological activities, and structure-activity relationships.
 ...
PMID:Phytochemicals and biological activities of Dipsacus species. 2140 25

We propose a biochemical mechanism for celiac disease and non-celiac gluten sensitivity that may rationalize many of the extradigestive disorders not explained by the current immunogenetic model. Our hypothesis is based on the homology between the 33-mer gliadin peptide and a component of the NMDA glutamate receptor ion channel - the human GRINA protein - using BLASTP software. Based on this homology the 33-mer may act as a natural antagonist interfering with the normal interactions of GRINA and its partners. The theory is supported by numerous independent data from the literature, and provides a mechanistic link with otherwise unrelated disorders, such as cleft lip and palate, thyroid dysfunction, restless legs syndrome, depression, ataxia, hearing loss, fibromyalgia, dermatitis herpetiformis, schizophrenia, toxoplasmosis, anemia, osteopenia, Fabry disease, Barret's adenocarcinoma, neuroblastoma, urinary incontinence, recurrent miscarriage, cardiac anomalies, reduced risk of breast cancer, stiff person syndrome, etc. The hypothesis also anticipates better animal models, and has the potential to open new avenues of research.
...
PMID:Extraintestinal manifestations of celiac disease: 33-mer gliadin binding to glutamate receptor GRINA as a new explanation. 2699 Feb 86

In different parts of the world, pregabalin is an approved treatment for neuropathic pain syndromes, fibromyalgia, partial-onset seizures, and generalized anxiety disorder. Few studies have examined the safety of pregabalin exposure during pregnancy. Among 4 studies identified through a PubMed search conducted in September 2018, one small study (exposed n = 30) recorded a major malformation rate of 3.3%, which was similar to that in unexposed controls. Another small study (exposed n = 30) recorded increased rates of spontaneous abortion (23.3%), preterm birth (25.0%), and major malformations (7.7%), none of which reached statistical significance even in unadjusted analyses. A third study (exposed n = 116) identified a significantly increased rate of major malformations (6.0%) but no increase in the rates of other adverse birth outcomes. The fourth and largest study (exposed n = 477 and n = 174; 2 datasets), which also presented the best statistical analysis, found no increase in the major malformation risk associated with pregabalin exposure. A subjective conclusion is that there is no clear signal that pregabalin exposure during pregnancy is associated with adverse gestational outcomes; however, this conclusion is limited by the consideration that all analyses were underpowered. Pregabalin use in pregnancy is therefore best restricted to circumstances in which the risk-benefit ratio is clearly favorable, and then, only after shared decision-making.
 ...
PMID:Safety of Pregabalin in Pregnancy. 3028 31